Novartis Pharmaceuticals Patents – Insights & Stats

Novartis Pharmaceuticals has a total of 191 patents globally, out of which 112 have been granted. Of these 191 patents, more than 40% patents are active. The United States of America is where Novartis Pharmaceuticals has filed the maximum number of patents, followed by the United Kingdom and Australia. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Novartis Pharmaceuticals.

Novartis Pharmaceuticals is a sub-part of Novartis was founded in the year 1996. Novartis Pharmaceuticals operates as a pharmaceutical company. The business conducts research, develops, produces, and markets patent-protected prescription medications for critical medical conditions including the heart, central nervous system, cancer, ophthalmology, organ transplantation, and respiratory systems.

Do read about some of the most popular patents of Novartis Pharmaceuticals which have been covered by us in this article and also you can find Novartis Pharmaceuticals patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Novartis Pharmaceuticals patent portfolio.

How many patents does Novartis Pharmaceuticals have?

Novartis Pharmaceuticals has a total of 191 patents globally. These patents belong to 93 unique patent families. Out of 191 patents, 78 patents are active.

How Many Patents did Novartis Pharmaceuticals File Every Year?

Novartis Pharmaceuticals Patents Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantNovartis Pharmaceuticals Applications FiledNovartis Pharmaceuticals Patents Granted

Which Novartis Pharmaceuticals Drug Patents are Expiring in the Next 10 Years?

The patent no. US7378423B2 which is expiring in May, 2027, describing cancer-fighting agent inhibiting cell growth in colorectal, pancreatic, lung, breast cancers, etc. Contains a pyrimidine compound that induces p15 and/or p27 proteins and/or inhibits MEK.

Given below is the list of few drugs patented by Novartis Pharmaceuticals accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.

Drug NamePatent NumberPatent TitlePatent Expiration
MekinistUS7378423B2Pyrimidine compound and medical…May, 2027
XiidraUS8367701B2Crystalline pharmaceutical and meth…Apr, 2029
PromactaUS8052994B23′-[(2Z)-[1-(3,4-dimethylphenyl)-1…Feb, 2028
TafinlarUS10869869B2Method of adjuvant cancer treatment…Aug, 2033
TasignaUS8293756B2Pharmaceutical compositions comp…Sep, 2027

How many Novartis Pharmaceuticals patents are Alive/Dead?

Novartis Pharmaceuticals Patents Portfolio

How Many Patents did Novartis Pharmaceuticals File in Different Countries?

Novartis Pharmaceuticals Worldwide Patents

Countries in which Novartis Pharmaceuticals Filed Patents

United States Of America181
United Kingdom1

Where are the Research Centres of Novartis Pharmaceuticals Patents Located?

Research Centres of Novartis Pharmaceuticals Patents

10 Best Novartis Pharmaceuticals Patents

US7682219B2 is the most popular patent in the Novartis Pharmaceuticals portfolio. It has received 697 citations so far from companies like Monsanto Technology, Athenix Corp, and Agrigenetics.

Below is the list of 10 most cited patents of Novartis Pharmaceuticals:

Publication NumberCitation Count

How many inventions of other companies were rejected due to Novartis Pharmaceuticals patents?

The statistics below share strategic R&D insights. It tells the companies that were trying to protect inventions similar to Novartis Pharmaceuticals invention. They couldn’t because Novartis Pharmaceuticals had protected those before them.

Examiners at the USPTO referred 39 Novartis Pharmaceuticals patents in 147 rejections (35 USC § 102 or 35 USC § 103 types).

The top citing companies in the Novartis Pharmaceuticals patent portfolio are Nissan Chemical, Silvergate Pharmaceuticals, and Dupont.

List of the Companies whose Patents were rejected citing Novartis Pharmaceuticals –

CompanyNumber of Patent Applications that faced Rejection Citing Novartis Pharmaceuticals PatentsNumber of Rejections (102 & 103)
Nissan Chemical1018
Silvergate Pharmaceuticals55
Eci Pharmaceuticals35
Supernus Pharmaceuticals36
Rush University Medical Center26
Crystal Pharmatech23
National Jewish Health22
Mankind Pharma24

Count of 102 and 103 Type Rejections based on Novartis Pharmaceuticals Patents

Top Novartis Pharmaceuticals Patents used in Rejecting Most Patent Applications

Patent NumberCount of Rejected Applications

What Percentage of Novartis Pharmaceuticals US Patent Applications were Granted?

Novartis Pharmaceuticals (Excluding its subsidiaries) has filed 304 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 156 have been granted leading to a grant rate of 59.54%.

Below are the key stats of Novartis Pharmaceuticals patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Novartis Pharmaceuticals?

Law FirmTotal ApplicationsSuccess Rate
Shire C O Troutman Sanders170%
Troutman Pepper90%
K&L Gates5100%
Mccarter & English425%
Fish & Richardson3100%
Genomics Institute3100%

What are Novartis Pharmaceuticals key innovation segments?

What Technologies are Covered by Novartis Pharmaceuticals?

The chart below distributes patents filed by Novartis Pharmaceuticals in different countries on the basis of the technology protected in patents. It also represents the markets where Novartis Pharmaceuticals thinks it’s important to protect particular technology inventions.

R&D Focus: How has Novartis Pharmaceuticals search focus changed over the years?


Interested in knowing about the areas of innovation that are being protected by Novartis Pharmaceuticals?

Related Articles

KnowBe4 Patents – Insights & Stats (Updated 2024)

KnowBe4 has a total of 199 patents globally, out of which 122 have been granted. Of these 199 patents, more than 87% patents are active. United States of America is where KnowBe4 has filed the maximum number of patents, followed by Europe and Austria. Parallelly, United States of America seems

Read More »

Cloudera Patents – Insights & Stats (Updated 2024)

Cloudera has a total of 130 patents globally, out of which 92 have been granted. Of these 130 patents, more than 85% patents are active. United States of America is where Cloudera has filed the maximum number of patents, followed by Europe and Canada. Parallelly, United States of America seems

Read More »

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.